A Phase 1 Comparative Study of E2022 Current and New Patch Formulations

Overview

The purpose of this study is to investigate the safety and pharmacokinetics of new patch formulation (tape) of E2022 by conducting patch test.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2012

Interventions

  • Drug: E2022- Current Formula Tape
    • Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test. Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days.
  • Drug: E2022- New Formula Tape
    • Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test. Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days.
  • Drug: E2022 Matching Placebo- Current Formula Tape
  • Drug: E2022 Matching Placebo- New Formula Tape

Arms, Groups and Cohorts

  • Experimental: E2022- Tape Formulation
  • Placebo Comparator: Matching Placebo E2022
    • Matching Placebo
  • Active Comparator: E2022- New Formulation
  • Placebo Comparator: Placebo E2022- New Formulation
    • Matching Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Number of Adverse Events
    • Time Frame: 10 days (Cohort I) and 40 days (Cohort II)
  • Frequency of Adverse Events
    • Time Frame: 10 days (Cohort I) and 40 days (Cohort II)

Secondary Measures

  • Pharmacokinetic Parameter: Cmax
    • Time Frame: 40 days (Cohort II)
  • Pharmacokinetic Parameter: Tmax
    • Time Frame: 40 days (Cohort II)
  • Pharmacokinetic Parameter: AUC
    • Time Frame: 40 days (Cohort II)

Participating in This Clinical Trial

Inclusion criteria 1. Non-smoker or not smoking for 4 weeks or longer before study treatment 2. BMI at screening is greater than or equal to 18.5 kg/m2 or less than 25.0 kg/m2 3. With written informed consent 4. Given full explanation of this study and is willing to and able to comply with study requirements. Exclusion criteria (Cohort 1 and 2): 1. Have a disorder which affects the evaluation of study drug such as psychiatric, gastrointestinal, hepatic, renal, respiratory, endocrinological, hematological, neurological, or cardiovascular system, or congenital metabolic abnormality 2. Have a clinically significant abnormality or organ dysfunction 3. Have a history of allergy to drug or food requiring medical treatment or seasonal allergy at screening 4. Have a history or complication of contact dermatitis or atopic dermatitis 5. Have hairy back or have shaved within 4 weeks before study treatment 6. Have a skin disease (e.g., eczema, dermatitis, dyschromatosis), or skin damage (e.g., injury, scar, or sun burn) which may affect skin assessment 7. Have a history or suspected to have drug or alcohol dependence, or positive for urine drug screen at baseline or a day before screening 8. Have had caffeine-containing drink or food, or alcohol within 72 hours before study treatment 9. Have used liquid product (including cosmetics), or applied patch, tape, or bandage on the back within 4 weeks before study treatment 10. Had hard exercise at least 5 days a week or a 1-hour or longer hard exercise within 2 weeks before study treatment (Only Cohort 2): 1. Meet QTc of greater than 450 milliseconds at screening or immediately before study treatment 2. Had nutrients, herb preparations (e.g. oriental medicine), other food or drink (e.g., grapefruit-containing juice) which may affect the activity of drug-metabolizing enzyme or transporter within 2 weeks before study treatment 3. Had St. John's Wort-containing preparation within 4 weeks before Period 1 application

Gender Eligibility: Male

Minimum Age: 20 Years

Maximum Age: 39 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Eisai Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Hidetaka Hiramatsu, Study Director, Eisai Co., Ltd.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.